Get the Stockscreener App
0.3604
12.10%
-0.0495
Processa Pharmaceuticals Inc stock is traded at $0.3604, with a volume of 4.82M.
It is down -12.10% in the last 24 hours and up +79.65% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.4098
Open:
$0.396
24h Volume:
4.82M
Relative Volume:
0.51
Market Cap:
$18.17M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.0748
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
-8.28%
1M Performance:
+79.65%
6M Performance:
+41.81%
1Y Performance:
-72.92%
1-Day Range:
$0.36
$0.42
1-Week Range:
$0.3171
$0.4432
52-Week Range:
$0.15
$1.50
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.3609 | 22.11M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.14 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
485.18 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.38 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
827.18 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.93 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Can you recover from losses in Processa Pharmaceuticals Inc.July 2025 Breakouts & Fast Entry Momentum Alerts - newser.com
What data driven models say about Processa Pharmaceuticals Inc.’s futureWeekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
Is Processa Pharmaceuticals Inc. stock a defensive play in 2025July 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Order flow analysis tools used on Processa Pharmaceuticals Inc.Earnings Summary Report & AI Driven Price Predictions - newser.com
Can volume confirm reversal in Processa Pharmaceuticals Inc.Bull Run & Free Long-Term Investment Growth Plans - newser.com
What moving averages say about Processa Pharmaceuticals Inc.Weekly Gains Report & Risk Controlled Swing Alerts - newser.com
Should you wait for a breakout in Processa Pharmaceuticals Inc.Market Sentiment Report & Community Trade Idea Sharing Platform - newser.com
Applying big data sentiment scoring on Processa Pharmaceuticals Inc.July 2025 Trade Ideas & Fast Gaining Stock Reports - newser.com
Top chart patterns to watch in Processa Pharmaceuticals Inc.July 2025 Gainers & Consistent Income Trade Ideas - newser.com
Is Processa Pharmaceuticals Inc. stock a buy before product launchesEarnings Recap Summary & AI Driven Stock Price Forecasts - newser.com
Published on: 2025-10-14 00:40:32 - newser.com
Is Processa Pharmaceuticals Inc. still worth holding after the dipJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - newser.com
Using economic indicators to assess Processa Pharmaceuticals Inc. potentialPortfolio Gains Summary & Technical Pattern Alert System - newser.com
Using AI based signals to follow Processa Pharmaceuticals Inc.Market Weekly Review & Momentum Based Trading Ideas - newser.com
Can swing trading help recover from Processa Pharmaceuticals Inc. lossesJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Live market analysis of Processa Pharmaceuticals Inc.Trade Performance Summary & AI Forecast for Swing Trade Picks - newser.com
Forecasting Processa Pharmaceuticals Inc. price range with options dataWeekly Profit Analysis & Weekly High Momentum Picks - newser.com
How Processa Pharmaceuticals Inc. stock reacts to inflationary pressures2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com
Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight? - Sahm
Biotech Stocks Surge After Hours: PCSA, PALI, And QTTB Lead On Volume And Speculation - Nasdaq
TELO, PCSA, RVPH, NMTC, BRTX Jump In After-Hours Trading On Light News Flow And Select Updates - RTTNews
Momentum divergence signals in Processa Pharmaceuticals Inc. chart2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-10-05 04:03:55 - newser.com
Can machine learning forecast Processa Pharmaceuticals Inc. recovery2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Published on: 2025-10-03 04:24:10 - newser.com
Published on: 2025-10-03 02:09:35 - newser.com
Processa Pharmaceuticals' chief business officer buys $34,691 in stock - MSN
Ulcerated Necrobiosis Lipoidica Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Processa Pharmaceuticals - The Globe and Mail
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
3.49%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):